Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer’s disease patients and controls.
27 January, 2016
The apolipoprotein E (ApoE) ε4 allele is the strongest risk factor of sporadic Alzheimer’s disease (AD), however, the fluid concentrations of ApoE and its different isoforms (ApoE2, ApoE3 and ApoE4) in AD patients and among APOE genotypes (APOE ε2, ε3, ε4) remain controversial. Using a novel mass spectrometry-based method, we quantified total ApoE and specific ApoE isoform concentrations and potential associations
Read the article
Flt3 ligand does not differentiate between Parkinsonian disorders.
BACKGROUND: Differential diagnosis of parkinsonian disorders is challenging because of overlapping symptoms, especially during early stages of disease. No validated biomarkers are available for early and accurate diagnosis of multiple system atrophy and other parkinsonian disorders. It has been reported that flt3 ligand levels in cerebrospinal fluid could clearly differentiate patients with Parkinson’s disease from
Read the article
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Background Phosphorylcholine is one of the major epitopes of oxidised low density lipoprotein. Low levels of IgM antibodies against phosphorylcholine (anti-PC) are associated with development of myocardial infarction and stroke. It has been shown that patients with Alzheimer’s disease and other dementias have significantly lower serum anti-PC levels compared to controls, suggesting that low levels
Read the article
Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjects.
In a large multicentre sample of cognitively normal subjects, as a function of age, gender and APOE genotype, we studied the frequency of abnormal cerebrospinal fluid levels of Alzheimer’s disease biomarkers including: total tau, phosphorylated tau and amyloid-β1-42. Fifteen cohorts from 12 different centres with either enzyme-linked immunosorbent assays or Luminex® measurements were selected for
Read the article
Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy
INTRODUCTION: The aim of this study is to identify disease-specific changes of the thalamus, basal ganglia, pons, and midbrain in patients with progressive supranuclear palsy (PSP), Parkinson’s disease (PD), and multiple system atrophy with predominant parkinsonism (MSA-P) using diffusion tensor imaging and volumetric analysis. METHODS: MRI diffusion and volumetric data were acquired in a derivation
Read the article
Parkinson’s Disease Case Ascertainment in the EPIC Cohort: The NeuroEPIC4PD Study.
BACKGROUND: Large epidemiological prospective studies represent an important opportunity for investigating risk factors for rare diseases such as Parkinson’s disease (PD). Here we describe the procedures we used for ascertaining PD cases in the EPIC (European Prospective Investigation into Cancer and Nutrition) study. METHODS: The following three-phase procedure was used: (1) elaboration of a NeuroEPIC4PD
Read the article
Cerebral white matter lesions – associations with Aβ isoforms and amyloid PET
Small vessel disease (SVD) and amyloid deposition may promote each other, with a potential association between SVD and altered production or clearance of β-amyloid (Aβ) a ecting its cleavage products. We investigated the relationship between SVD, multiple isoforms of Aβ in cerebrospinal uid (CSF) and cortical Aβ in 831 subjects with cognitive performance ranging from
Read the article
Associations between TOMM40 Poly-T Repeat Variants and Dementia in Cases with Parkinsonism
BACKGROUND: Mitochondrial dysfunction has been implicated in the pathophysiology of Parkinson’s disease (PD)-related pathologies. OBJECTIVE: To investigate the role of the Translocase of the Outer Mitochondrial Membrane 40 homolog (TOMM40) variants in PD without dementia (PDND), PD with dementia (PDD) and in Dementia with Lewy bodies (DLB). METHODS: 248 individuals, including 92 PDND, 55 PDD,
Read the article
Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer’s disease
OBJECTIVE: Widespread implementation of cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD) in clinical settings requires improved accuracy for diagnosis of prodromal disease and for distinguishing AD from non-AD dementias. Novel and promising CSF biomarkers include neurogranin, a marker of synaptic degeneration, and YKL-40, a marker of neuroinflammation. METHODS: CSF neurogranin and YKL-40 were measured
Read the article